NEW DELHI - Indian generics giant Sun Pharmaceutical Industries Ltd. has bolstered its diabetes portfolio by announcing a tie-up with UK-based AstraZeneca PLC to distribute in India a new SGLT2 inhibitor for the most common type 2 form of the disease in a country, which has the second-highest number of diabetics globally.
Dapagliflozin Alliance Targets Surging Indian Diabetes Market
AstraZeneca has struck an agreement with India’s Sun Pharma under which the two companies will promote and distribute the UK-based firm’s diabetes drug dapagliflozin under different brand names. The deal means AstraZeneca can benefit from Sun’s wide distribution network to penetrate India’s rapidly growing diabetes sector while retaining intellectual property rights.